Human Milk-Based Fortification No Aid for Extremely Preterm Infants

10 Jan 2024
www.drugs.com
Clinical ResultClinical Study
WEDNESDAY, Jan. 10, 2024 -- Human milk-based fortification does not aid outcomes in extremely preterm infants fed exclusively with breast milk, according to a study published online Jan. 2 in eClinicalMedicine.
Georg Bach Jensen, from Linköping University and Crown Princess Victoria Children's Hospital in Sweden, and colleagues randomly assigned (1:1) 228 extremely preterm infants (born between gestational week 22 + 0 and 27 + 6) who were fed exclusively human breast milk (mother's own and/or donor milk) to receive targeted fortification with either human milk-based fortifier (HMBF) or bovine milk-based fortifier (BMBF).
The researchers found that 35.7 percent of infants assigned to HMBF fulfilled the criteria of either necrotizing enterocolitis, sepsis, or death versus 34.5 percent of infants assigned to BMBF (odds ratio, 1.05; 95 percent confidence interval, 0.61 to 1.81; P = 0.86). There were no significant differences between the groups for adverse events.
"We acknowledge that the results of the present trial may need to be verified by other studies," the authors write. "Further, potential effects on growth and neurodevelopmental outcomes still remain to be evaluated, and such follow-up analyses from this study are ongoing."
One author disclosed ties to Prolacta Bioscience, which partially funded the study.
Abstract/Full Text
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.